DGIdb - CYP3A5 Gene Record

CYP3A5 1577 Druggable Genome

Alternate Names:

1577
CYTOCHROME P450 FAMILY 3 SUBFAMILY A MEMBER 5
CYP3A5
CP35
CYPIIIA5
P450PCN3
PCN3
605325
2638
ENSG00000106258
OTTHUMG00000156724
P20815
CP3A5_HUMAN
CYTOCHROME P450 3A5
Cytochrome P450 HLp2
Cytochrome P450-PCN3
CYTOCHROME P450 3A5 (EC 1.14.14.1) (CYPIIIA5) (P450-PCN3) (HLP2). [SOURCE:UNIPROT/SWISSPROT;ACC:P20815]
PA131

Gene Info:

Uniprot Evidence	1: Evidence at protein level
Uniprot Status	Swiss-Prot
Human Readable Name	DRUGGABLE GENOME
Interpro Short Name	Cyt_P450
Human Readable Name	CYTOCHROME P450
Interpro Acc	IPR001128
Interpro Type	Family
Interpro Name	Cytochrome P450
Target Class	Enzymes
Target Subclass	EC:1.14.14.1
Gene Biotype	PROTEIN_CODING

(8 More Sources)

Gene Categories: Category Details

DRUGGABLE GENOME
CYTOCHROME P450
ENZYME

Publications:

Porcelli S et al., 2016, Possible biomarkers modulating haloperidol efficacy and/or tolerability., Pharmacogenomics
Zanger UM et al., 2008, Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation., Anal Bioanal Chem
Bailey KM et al., 2010, Hepatic metabolism and transporter gene variants enhance response to rosuvastatin in patients with acute myocardial infarction: the GEOSTAT-1 Study., Circ Cardiovasc Genet
Ueshima S et al., 2018, Population pharmacokinetics and pharmacogenomics of apixaban in Japanese adult patients with atrial fibrillation., Br J Clin Pharmacol
Ueshima S et al., 2017, Impact of ABCB1, ABCG2, and CYP3A5 polymorphisms on plasma trough concentrations of apixaban in Japanese patients with atrial fibrillation., Pharmacogenet Genomics
Kim KA et al., 2006, Effect of CYP3A5*3 genotype on the pharmacokinetics and pharmacodynamics of amlodipine in healthy Korean subjects., Clin Pharmacol Ther
Li et al., 2007, Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes., Clin. Cancer Res.
Chan EC et al., 2012, Interaction of lapatinib with cytochrome P450 3A5., Drug Metab Dispos
Barbara JE et al., 2013, Metabolism-dependent inhibition of CYP3A4 by lapatinib: evidence for formation of a metabolic intermediate complex with a nitroso/oxime metabolite formed via a nitrone intermediate., Drug Metab Dispos
Kim KA et al., 2014, Influence of ABCB1 and CYP3A5 genetic polymorphisms on the pharmacokinetics of quetiapine in healthy volunteers., Pharmacogenet Genomics
Oshiro C et al., 2009, Taxane pathway., Pharmacogenet Genomics
Luzum JA et al., 2015, Individual and Combined Associations of Genetic Variants in CYP3A4, CYP3A5, and SLCO1B1 With Simvastatin and Simvastatin Acid Plasma Concentrations., J Cardiovasc Pharmacol
Tsamandouras N et al., 2014, Identification of the effect of multiple polymorphisms on the pharmacokinetics of simvastatin and simvastatin acid using a population-modeling approach., Clin Pharmacol Ther
Hu M et al., 2013, Associations between the genotypes and phenotype of CYP3A and the lipid response to simvastatin in Chinese patients with hypercholesterolemia., Pharmacogenomics
Zuccaro P et al., 2007, Tolerability of statins is not linked to CYP450 polymorphisms, but reduced CYP2D6 metabolism improves cholesteraemic response to simvastatin and fluvastatin., Pharmacol Res
Kim KA et al., 2007, Effect of polymorphic CYP3A5 genotype on the single-dose simvastatin pharmacokinetics in healthy subjects., J Clin Pharmacol
Fiegenbaum et al., 2005, The role of common variants of ABCB1, CYP3A4, and CYP3A5 genes in lipid-lowering efficacy and safety of simvastatin treatment., Clin. Pharmacol. Ther.
Kivistö KT et al., 2004, Lipid-lowering response to statins is affected by CYP3A5 polymorphism., Pharmacogenetics
Pu J et al., 2019, Correlation between gene polymorphism and opioid efficacy in patients with gastric or intestinal cancer., Eur Rev Med Pharmacol Sci
Usui et al., 2003, Induction of CYP3As in HepG2 cells by several drugs. Association between induction of CYP3A4 and expression of glucocorticoid receptor., Biol. Pharm. Bull.
Cabaleiro T et al., 2013, Polymorphisms influencing olanzapine metabolism and adverse effects in healthy subjects., Hum Psychopharmacol
Ashirmetov et al., [The role of the parasympathetic nervous system in the regulation of microsomal monooxygenase activity in the liver of rats]., Fiziol Zh
Tu et al., 1983, Induction of a high affinity nitrosamine demethylase in rat liver microsomes by acetone and isopropanol., Chem. Biol. Interact.
Stamer UM et al., 2011, CYP2D6- and CYP3A-dependent enantioselective plasma concentrations of ondansetron in postanesthesia care., Anesth Analg
Yin OQ et al., 2010, CYP3A5 but not CYP2D6 polymorphism contributes significantly to the variability in dextropropoxyphene disposition., J Clin Pharmacol
Haas DM et al., 2013, Nifedipine pharmacokinetics are influenced by CYP3A5 genotype when used as a preterm labor tocolytic., Am J Perinatol
Abell LM et al., 2011, Dissecting the activation of thienopyridines by cytochromes P450 using a pharmacodynamic assay in vitro., J Pharmacol Exp Ther
Gozalo C et al., 2011, Pharmacogenetics of toxicity, plasma trough concentration and treatment outcome with nevirapine-containing regimen in anti-retroviral-naïve HIV-infected adults: an exploratory study of the TRIANON ANRS 081 trial., Basic Clin Pharmacol Toxicol
Ciccacci C et al., 2010, Nevirapine-induced hepatotoxicity and pharmacogenetics: a retrospective study in a population from Mozambique., Pharmacogenomics
Mahungu T et al., 2009, Cytochrome P450 2B6 516G-->T is associated with plasma concentrations of nevirapine at both 200 mg twice daily and 400 mg once daily in an ethnically diverse population., HIV Med
Hu L et al., 2016, Genetic variation of CYP3A5 influences paclitaxel/carboplatin-induced toxicity in Chinese epithelial ovarian cancer patients., J Clin Pharmacol
Leskelä S et al., 2011, Polymorphisms in cytochromes P450 2C8 and 3A5 are associated with paclitaxel neurotoxicity., Pharmacogenomics J
García-Martín et al., 2006, Acquired resistance to the anticancer drug paclitaxel is associated with induction of cytochrome P450 2C8., Pharmacogenomics
Willrich MA et al., 2008, CYP3A53A allele is associated with reduced lowering-lipid response to atorvastatin in individuals with hypercholesterolemia., Clin Chim Acta
Thompson JF et al., 2005, An association study of 43 SNPs in 16 candidate genes with atorvastatin response., Pharmacogenomics J
Wilke RA et al., 2005, Relative impact of CYP3A genotype and concomitant medication on the severity of atorvastatin-induced muscle damage., Pharmacogenet Genomics
Wang P et al., 2015, Effects of CYP3A4/5 and ABCB1 genetic polymorphisms on carbamazepine metabolism and transport in Chinese patients with epilepsy treated with carbamazepine in monotherapy and bitherapy., Epilepsy Res
Zhu X et al., 2014, Effects of major transporter and metabolizing enzyme gene polymorphisms on carbamazepine metabolism in Chinese patients with epilepsy., Pharmacogenomics
Saruwatari J et al., 2014, Pregnane X receptor and hepatocyte nuclear factor 4α polymorphisms are cooperatively associated with carbamazepine autoinduction., Pharmacogenet Genomics
Puranik YG et al., 2013, Association of carbamazepine major metabolism and transport pathway gene polymorphisms and pharmacokinetics in patients with epilepsy., Pharmacogenomics
Thorn CF et al., 2011, PharmGKB summary: carbamazepine pathway., Pharmacogenet Genomics
Hennessy EJ et al., 2015, Identification and Optimization of Benzimidazole Sulfonamides as Orally Bioavailable Sphingosine 1-Phosphate Receptor 1 Antagonists with in Vivo Activity., J Med Chem
Bustos ML et al., 2016, Polymorphisms in CYP1A1 and CYP3A5 Genes Contribute to the Variability in Granisetron Clearance and Exposure in Pregnant Women with Nausea and Vomiting., Pharmacotherapy
Zhou X et al., 2018, Effect of breviscapine on CYP3A metabolic activity in healthy volunteers., Eur J Clin Pharmacol
Vyhlidal CA et al., 2015, Variability in Expression of CYP3A5 in Human Fetal Liver., Drug Metab Dispos
Seng KY et al., 2014, CYP3A5*3 and bilirubin predict midazolam population pharmacokinetics in Asian cancer patients., J Clin Pharmacol
Elens L et al., 2013, CYP3A4 intron 6 C>T SNP (CYP3A4*22) encodes lower CYP3A4 activity in cancer patients, as measured with probes midazolam and erythromycin., Pharmacogenomics
Sangkuhl K et al., 2011, Platelet aggregation pathway., Pharmacogenet Genomics
Granfors et al., 2006, Differential inhibition of cytochrome P450 3A4, 3A5 and 3A7 by five human immunodeficiency virus (HIV) protease inhibitors in vitro., Basic Clin. Pharmacol. Toxicol.
Zubiaur P et al., 2020, Effect of Sex, Use of Pantoprazole and Polymorphisms in SLC22A1, ABCB1, CES1, CYP3A5 and CYP2D6 on the Pharmacokinetics and Safety of Dabigatran., Adv Ther
Sukasem C et al., 2014, Pharmacogenetics and clinical biomarkers for subtherapeutic plasma efavirenz concentration in HIV-1 infected Thai adults., Drug Metab Pharmacokinet
Elens L et al., 2010, Influence of host genetic factors on efavirenz plasma and intracellular pharmacokinetics in HIV-1-infected patients., Pharmacogenomics
Chen J et al., 2010, CYP2B6 polymorphism and nonnucleoside reverse transcriptase inhibitor plasma concentrations in Chinese HIV-infected patients., Ther Drug Monit
Haas DW et al., 2005, Pharmacogenetics of long-term responses to antiretroviral regimens containing Efavirenz and/or Nelfinavir: an Adult Aids Clinical Trials Group Study., J Infect Dis
Haas DW et al., 2004, Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study., AIDS
Ehmann F et al., 2014, European Medicines Agency initiatives and perspectives on pharmacogenomics., Br J Clin Pharmacol
Zhao Y et al., 2009, Effects of CYP3A5, MDR1 and CACNA1C polymorphisms on the oral disposition and response of nimodipine in a Chinese cohort., Eur J Clin Pharmacol
Rodríguez-Jiménez C et al., 2017, Influence of genetic polymorphisms of CYP3A5 and ABCB1 on sirolimus pharmacokinetics, patient and graft survival and other clinical outcomes in renal transplant., Drug Metab Pers Ther
Li Y et al., 2015, CYP3A5 and ABCB1 genotype influence tacrolimus and sirolimus pharmacokinetics in renal transplant recipients., Springerplus
Emoto C et al., 2015, The impact of CYP3A5*3 polymorphism on sirolimus pharmacokinetics: insights from predictions with a physiologically-based pharmacokinetic model., Br J Clin Pharmacol
Woillard JB et al., 2013, Effect of CYP3A422, POR28, and PPARA rs4253728 on sirolimus in vitro metabolism and trough concentrations in kidney transplant recipients., Clin Chem
Sam WJ et al., 2011, Associations of ABCB1 3435C>T and IL-10-1082G>A polymorphisms with long-term sirolimus dose requirements in renal transplant patients., Transplantation
Miao LY et al., 2008, Association study of ABCB1 and CYP3A5 gene polymorphisms with sirolimus trough concentration and dose requirements in Chinese renal transplant recipients., Biopharm Drug Dispos
Le Meur Y et al., 2006, CYP3A5*3 influences sirolimus oral clearance in de novo and stable renal transplant recipients., Clin Pharmacol Ther
Anglicheau D et al., 2005, Consequences of genetic polymorphisms for sirolimus requirements after renal transplant in patients on primary sirolimus therapy., Am J Transplant
Saiz-Rodríguez M et al., 2019, Polymorphisms associated with fentanyl pharmacokinetics, pharmacodynamics and adverse effects., Basic Clin Pharmacol Toxicol
Ishida T et al., 2016, Relationship between the plasma fentanyl and serum 4β-hydroxycholesterol based on CYP3A5 genotype and gender in patients with cancer pain., Drug Metab Pharmacokinet
Tanaka N et al., 2014, Impact of CYP3A5*3 on plasma exposure and urinary excretion of fentanyl and norfentanyl in the early postsurgical period., Ther Drug Monit
Takashina Y et al., 2012, Impact of CYP3A5 and ABCB1 gene polymorphisms on fentanyl pharmacokinetics and clinical responses in cancer patients undergoing conversion to a transdermal system., Drug Metab Pharmacokinet
Lesche D et al., 2015, Influence of CYP3A5 genetic variation on everolimus maintenance dosing after cardiac transplantation., Clin Transplant
Schoeppler KE et al., 2014, The impact of genetic polymorphisms, diltiazem, and demographic variables on everolimus trough concentrations in lung transplant recipients., Clin Transplant
Naito T et al., 2011, CYP3A5*3 affects plasma disposition of noroxycodone and dose escalation in cancer patients receiving oxycodone., J Clin Pharmacol
Shon JH et al., 2011, The disposition of three phosphodiesterase type 5 inhibitors, vardenafil, sildenafil, and udenafil, is differently influenced by the CYP3A5 genotype., Pharmacogenet Genomics
Kim HR et al., 2013, Pharmacogenetic determinants associated with sunitinib-induced toxicity and ethnic difference in Korean metastatic renal cell carcinoma patients., Cancer Chemother Pharmacol
Garcia-Donas J et al., 2011, Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study., Lancet Oncol
Adeagbo BA et al., 2016, Influence of CYP3A5*3 and ABCB1 C3435T on clinical outcomes and trough plasma concentrations of imatinib in Nigerians with chronic myeloid leukaemia., J Clin Pharm Ther

VARDENAFIL CYP3A5

Interaction Score: 0.6

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
21934637

Sources:
PharmGKB
APIXABAN CYP3A5

Interaction Score: 0.6

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
29457840 28678049

Sources:
PharmGKB
PROPOXYPHENE CYP3A5

Interaction Score: 0.45

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
20133509 18695978

Sources:
PharmGKB
TADALAFIL CYP3A5

Interaction Score: 0.4

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
18695978

Sources:
PharmGKB
CLINDAMYCIN CYP3A5

Interaction Score: 0.4

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
18695978

Sources:
PharmGKB
ISOPROPYL ALCOHOL CYP3A5

Interaction Score: 0.4

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
6409434

Sources:
NCI
CHLORPHENIRAMINE CYP3A5

Interaction Score: 0.4

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
18695978

Sources:
PharmGKB
SALMETEROL CYP3A5

Interaction Score: 0.3

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
18695978

Sources:
PharmGKB
AMPRENAVIR CYP3A5

Interaction Score: 0.3

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16433896

Sources:
NCI
MELOXICAM CYP3A5

Interaction Score: 0.3

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
18695978

Sources:
PharmGKB
MEPERIDINE CYP3A5

Interaction Score: 0.3

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
18695978

Sources:
PharmGKB
HYDROMORPHONE CYP3A5

Interaction Score: 0.24

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
18695978

Sources:
PharmGKB
CYCLOBENZAPRINE CYP3A5

Interaction Score: 0.24

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
18695978

Sources:
PharmGKB
HYDROCODONE CYP3A5

Interaction Score: 0.24

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
18695978

Sources:
PharmGKB
SIBUTRAMINE CYP3A5

Interaction Score: 0.24

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
18695978

Sources:
PharmGKB
PRASUGREL CYP3A5

Interaction Score: 0.23

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
21828263

Sources:
PharmGKB FDA
OXYCODONE CYP3A5

Interaction Score: 0.2

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
21209234 18695978

Sources:
PharmGKB
TAMSULOSIN CYP3A5

Interaction Score: 0.2

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
18695978

Sources:
PharmGKB
SILDENAFIL CYP3A5

Interaction Score: 0.17

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
18695978

Sources:
PharmGKB
DONEPEZIL CYP3A5

Interaction Score: 0.17

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
18695978

Sources:
PharmGKB
EFAVIRENZ CYP3A5

Interaction Score: 0.17

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
24477223 20860463 20625352 16267764 15622315

Sources:
PharmGKB
PANTOPRAZOLE CYP3A5

Interaction Score: 0.17

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
18695978

Sources:
PharmGKB
BUSPIRONE CYP3A5

Interaction Score: 0.17

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
18695978

Sources:
PharmGKB
SUFENTANIL CYP3A5

Interaction Score: 0.17

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
31773688

Sources:
PharmGKB
LUMEFANTRINE CYP3A5

Interaction Score: 0.15

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
HYDROXYZINE CYP3A5

Interaction Score: 0.15

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
18695978

Sources:
PharmGKB
FENTANYL CYP3A5

Interaction Score: 0.14

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
30281924 27236640 24365989 22277678 18695978

Sources:
PharmGKB
LOSARTAN CYP3A5

Interaction Score: 0.13

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
18695978

Sources:
PharmGKB
DABIGATRAN CYP3A5

Interaction Score: 0.13

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
32564268

Sources:
PharmGKB
ONDANSETRON CYP3A5

Interaction Score: 0.13

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
21596874

Sources:
PharmGKB
ESOMEPRAZOLE CYP3A5

Interaction Score: 0.13

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
18695978

Sources:
PharmGKB
RIFAMPIN CYP3A5

Interaction Score: 0.13

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
26291341 18695978

Sources:
DTC PharmGKB
COBICISTAT CYP3A5

Interaction Score: 0.12

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Mechanism of Interaction Cytochrome P450 3A inhibitor

Direct Interaction yes

PMIDs:
None found

Sources:
ChemblInteractions
CLOPIDOGREL CYP3A5

Interaction Score: 0.12

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
21828263 20938371

Sources:
DTC PharmGKB
DOLUTEGRAVIR CYP3A5

Interaction Score: 0.12

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
ARTEMETHER CYP3A5

Interaction Score: 0.12

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
TERAZOSIN CYP3A5

Interaction Score: 0.12

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
18695978

Sources:
PharmGKB
MODAFINIL CYP3A5

Interaction Score: 0.12

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
18695978

Sources:
PharmGKB
BUPRENORPHINE CYP3A5

Interaction Score: 0.12

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
18695978

Sources:
PharmGKB
CARBAMAZEPINE CYP3A5

Interaction Score: 0.12

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
12673034 26421491 25495409 24384557 23252947 21738081 18695978

Sources:
NCI PharmGKB
SIMVASTATIN CYP3A5

Interaction Score: 0.11

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
26164721 24598718 23252946 18695978 17289397 17192506 16321621 15284534

Sources:
NCI PharmGKB
ISOTRETINOIN CYP3A5

Interaction Score: 0.11

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
18695978

Sources:
PharmGKB
ATROPINE CYP3A5

Interaction Score: 0.11

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
2128054

Sources:
NCI
NEVIRAPINE CYP3A5

Interaction Score: 0.1

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
21824325 20017669 19228205

Sources:
PharmGKB
AXITINIB CYP3A5

Interaction Score: 0.1

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
24433361

Sources:
PharmGKB
AMLODIPINE CYP3A5

Interaction Score: 0.1

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
17178265

Sources:
PharmGKB
SIROLIMUS CYP3A5

Interaction Score: 0.1

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
28245187 26543771 26256674 23974086 22094953 17941052 16815317 15707415

Sources:
PharmGKB
GRANISETRON CYP3A5

Interaction Score: 0.09

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
27809336

Sources:
PharmGKB
TRAZODONE CYP3A5

Interaction Score: 0.09

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
18695978

Sources:
PharmGKB
CLARITHROMYCIN CYP3A5

Interaction Score: 0.09

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
18695978

Sources:
PharmGKB
ROSUVASTATIN CYP3A5

Interaction Score: 0.09

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
20207952

Sources:
PharmGKB
BOCEPREVIR CYP3A5

Interaction Score: 0.09

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
MEDROXYPROGESTERONE ACETATE CYP3A5

Interaction Score: 0.09

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
18695978

Sources:
PharmGKB
TESMILIFENE CYP3A5

Interaction Score: 0.09

Interaction Types & Directionality:

n/a

Interaction Info:

Trial Name tesmilifene

Novel drug target Novel Target

PMIDs:
None found

Sources:
TdgClinicalTrial
MIDAZOLAM CYP3A5

Interaction Score: 0.08

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
28986606 25979262 24214410 23327575

Sources:
PharmGKB
VENLAFAXINE CYP3A5

Interaction Score: 0.08

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
18695978

Sources:
PharmGKB
NIMODIPINE CYP3A5

Interaction Score: 0.08

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
19205682

Sources:
PharmGKB
PIOGLITAZONE CYP3A5

Interaction Score: 0.08

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
18695978

Sources:
PharmGKB
LORATADINE CYP3A5

Interaction Score: 0.08

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
18695978

Sources:
PharmGKB
ATORVASTATIN CYP3A5

Interaction Score: 0.07

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
18727922 18695978 17289397 16103896 15900215 15284534

Sources:
PharmGKB
LOPINAVIR CYP3A5

Interaction Score: 0.07

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
ZOLPIDEM CYP3A5

Interaction Score: 0.07

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
MONTELUKAST CYP3A5

Interaction Score: 0.07

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
18695978

Sources:
PharmGKB
ESZOPICLONE CYP3A5

Interaction Score: 0.07

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
18695978

Sources:
PharmGKB
QUETIAPINE CYP3A5

Interaction Score: 0.07

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
24240480 18695978

Sources:
PharmGKB
LAPATINIB CYP3A5

Interaction Score: 0.07

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22511346 23404373

Sources:
DTC
ZIPRASIDONE CYP3A5

Interaction Score: 0.07

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
18695978

Sources:
PharmGKB
TRAMADOL CYP3A5

Interaction Score: 0.07

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
18695978

Sources:
PharmGKB
ERYTHROMYCIN CYP3A5

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
18695978

Sources:
PharmGKB
MIRTAZAPINE CYP3A5

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
18695978

Sources:
PharmGKB
SERTRALINE CYP3A5

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
18695978

Sources:
PharmGKB
AMIODARONE CYP3A5

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
18695978

Sources:
PharmGKB
CILOSTAZOL CYP3A5

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
PREDNISOLONE CYP3A5

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
12673034

Sources:
NCI
SUNITINIB CYP3A5

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
24013576 22015057

Sources:
PharmGKB
LANSOPRAZOLE CYP3A5

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
18695978

Sources:
PharmGKB
EVEROLIMUS CYP3A5

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
26458301 24628014

Sources:
PharmGKB
FLUOXETINE CYP3A5

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
18695978

Sources:
PharmGKB
LOVASTATIN CYP3A5

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
18695978 15284534

Sources:
PharmGKB
FENOFIBRATE CYP3A5

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
18695978

Sources:
PharmGKB
TRETINOIN CYP3A5

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
18695978

Sources:
PharmGKB
ALPRAZOLAM CYP3A5

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
18695978

Sources:
PharmGKB
DIAZEPAM CYP3A5

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
18695978

Sources:
PharmGKB
OMEPRAZOLE CYP3A5

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
18695978

Sources:
PharmGKB
CITALOPRAM CYP3A5

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
18695978

Sources:
PharmGKB
WARFARIN CYP3A5

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
18695978

Sources:
PharmGKB
RITONAVIR CYP3A5

Interaction Score: 0.03

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
PACLITAXEL CYP3A5

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
26179145 20212519 16753005

Sources:
NCI PharmGKB
PHENYTOIN CYP3A5

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
12673034

Sources:
NCI
FLUVASTATIN CYP3A5

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
HALOPERIDOL CYP3A5

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
27023437 18695978

Sources:
PharmGKB
PAROXETINE CYP3A5

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
NIFEDIPINE CYP3A5

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22875663

Sources:
PharmGKB
TRIAZOLAM CYP3A5

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
CYCLOSPORINE CYP3A5

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
12673034

Sources:
NCI
IMATINIB CYP3A5

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
27426203

Sources:
PharmGKB
CELECOXIB CYP3A5

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
18695978

Sources:
PharmGKB
PROGESTERONE CYP3A5

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
18695978

Sources:
PharmGKB
OLANZAPINE CYP3A5

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
23559402

Sources:
PharmGKB
GEFITINIB CYP3A5

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
17575239

Sources:
NCI
DOCETAXEL CYP3A5

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
21151855

Sources:
PharmGKB
CARBOPLATIN CYP3A5

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
26179145

Sources:
PharmGKB
VINCRISTINE CYP3A5

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB

Ensembl: ENSG00000106258
- Version: 101_38
Alternate Names:

CYP3A5 Ensembl Gene Name

Gene Info:

Gene Biotype PROTEIN_CODING

Publications:
RussLampel: ENSG00000106258
- Version: 26-July-2011
Alternate Names:

CYP3A5 Display Id

CYTOCHROME P450 3A5 (EC 1.14.14.1) (CYPIIIA5) (P450-PCN3) (HLP2). [SOURCE:UNIPROT/SWISSPROT;ACC:P20815] Description

ENSG00000106258 Ensembl Gene Id

Gene Info:

Human Readable Name DRUGGABLE GENOME

Gene Categories:

DRUGGABLE GENOME

Publications:
HopkinsGroom: P20815
- Version: 11-September-2012
Alternate Names:

CYP3A5 Uniprot Gene Name

ENSG00000106258 Ensembl Gene Id

CP3A5_HUMAN Uniprot Id

Gene Info:

Uniprot Evidence 1: Evidence at protein level

Uniprot Status Swiss-Prot

Human Readable Name DRUGGABLE GENOME

Gene Categories:

DRUGGABLE GENOME, CYTOCHROME P450

Publications:
TdgClinicalTrial: P20815
- Version: January-2014
Alternate Names:

CYP3A5 Gene Symbol

Gene Info:

Target Class Enzymes

Target Subclass EC:1.14.14.1

Publications:

PharmGKB: CYP3A5

Version: 18-August-2020

Alternate Names:

PA131 PharmGKB ID

Gene Info:

Publications:

Porcelli S et al., 2016, Possible biomarkers modulating haloperidol efficacy and/or tolerability., Pharmacogenomics

Zanger UM et al., 2008, Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation., Anal Bioanal Chem

Bailey KM et al., 2010, Hepatic metabolism and transporter gene variants enhance response to rosuvastatin in patients with acute myocardial infarction: the GEOSTAT-1 Study., Circ Cardiovasc Genet

NCI: CYP3A5

Version: 14-September-2017

Alternate Names:

Gene Info:

Publications:

Usui et al., 2003, Induction of CYP3As in HepG2 cells by several drugs. Association between induction of CYP3A4 and expression of glucocorticoid receptor., Biol. Pharm. Bull.

Rühl et al., 2004, Carotenoids and their metabolites are naturally occurring activators of gene expression via the pregnane X receptor., Eur J Nutr

Tu et al., 1983, Induction of a high affinity nitrosamine demethylase in rat liver microsomes by acetone and isopropanol., Chem. Biol. Interact.

DTC: CYP3A5

Version: 02-September-2020

Alternate Names:

Gene Info:

Publications:

Hennessy EJ et al., 2015, Identification and Optimization of Benzimidazole Sulfonamides as Orally Bioavailable Sphingosine 1-Phosphate Receptor 1 Antagonists with in Vivo Activity., J Med Chem

Barbara JE et al., 2013, Metabolism-dependent inhibition of CYP3A4 by lapatinib: evidence for formation of a metabolic intermediate complex with a nitroso/oxime metabolite formed via a nitrone intermediate., Drug Metab Dispos

Chan EC et al., 2012, Interaction of lapatinib with cytochrome P450 3A5., Drug Metab Dispos

ChemblInteractions: CYP3A5
- Version: chembl_23
Alternate Names:

CYP3A5 GENE_SYMBOL

Cytochrome P450 3A5 UNIPROT

CYPIIIA5 UNIPROT

Gene Info:

Publications:
HingoraniCasas: ENSG00000106258
- Version: 31-May-2017
Alternate Names:

ENSG00000106258 Gene Symbol

CYP3A5 Ensembl Id

Gene Info:

Gene Categories:

DRUGGABLE GENOME

Publications:
Tempus: CYP3A5
- Version: 11-November-2018
Alternate Names:

CYP3A5 Gene Symbol

Gene Info:

Gene Categories:

CLINICALLY ACTIONABLE

Publications:
Pharos: CYP3A5
- Version: 01-February-2022
Alternate Names:

Cytochrome P450 3A5 Gene Name

P20815 UniProt ID

Gene Info:

Gene Categories:

ENZYME

Publications:
FDA: CYP3A5
- Version: 04-September-2020
Alternate Names:

Gene Info:

Publications:

Mechanism of Interaction	Cytochrome P450 3A inhibitor
Direct Interaction	yes

CYP3A5	Display Id
CYTOCHROME P450 3A5 (EC 1.14.14.1) (CYPIIIA5) (P450-PCN3) (HLP2). [SOURCE:UNIPROT/SWISSPROT;ACC:P20815]	Description
ENSG00000106258	Ensembl Gene Id

CYP3A5	Uniprot Gene Name
ENSG00000106258	Ensembl Gene Id
CP3A5_HUMAN	Uniprot Id

CYP3A5 Gene Record

CYP3A5 1577 Druggable Genome

Alternate Names:

Gene Info:

Gene Categories: Category Details

Publications:

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 21934637

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 29457840 28678049

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 20133509 18695978

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 18695978

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 18695978

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 6409434

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 18695978

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 18695978

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 16433896

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 18695978

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 18695978

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 18695978

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 18695978

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 18695978

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 18695978

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 21828263

Sources: PharmGKB FDA

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 21209234 18695978

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 18695978

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

Interaction Types & Directionality:

n/a

PMIDs:
21934637

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
29457840 28678049

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
20133509 18695978

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
18695978

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
18695978

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
6409434

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
18695978

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
18695978

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
16433896

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
18695978

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
18695978

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
18695978

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
18695978

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
18695978

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
18695978

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
21828263

Sources:
PharmGKB FDA

Interaction Types & Directionality:

n/a

PMIDs:
21209234 18695978

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
18695978

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
18695978

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
18695978

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
24477223 20860463 20625352 16267764 15622315

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
18695978

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
18695978

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
31773688

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
18695978

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
30281924 27236640 24365989 22277678 18695978